Carbapenem-resistant enterobacteriaceae: A strategic roadmap for infection control

Infection Control and Hospital Epidemiology

Volumn 38, Issue 5, 2017, Pages 580-594

  Friedman, N Deborah ^a   Carmeli, Yehuda ^b,c,d   Walton, Aaron Lea ^a   Schwaber, Mitchell James ^c,d  

^a BARWON HEALTH   (Australia)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c MINISTRY OF HEALTH   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEMASE; CARBAPENEM DERIVATIVE;

ANTIMICROBIAL ACTIVITY; BACTERIAL TRANSMISSION; BACTERIUM DETECTION; BACTERIUM ISOLATION; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; FALLING; HAND WASHING; HUMAN; INFECTION CONTROL; INFECTION RISK; MORTALITY RATE; NONHUMAN; PATIENT TRANSPORT; PUBLIC HEALTH PROBLEM; REVIEW; SANITATION; UNIVERSAL PRECAUTION; WASTE MANAGEMENT; ANTIBIOTIC RESISTANCE; CROSS INFECTION; DRUG EFFECTS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; MICROBIOLOGY; PRACTICE GUIDELINE; PROCEDURES; SENTINEL SURVEILLANCE;

CARBAPENEMS; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; GUIDELINES AS TOPIC; HUMANS; INFECTION CONTROL; SENTINEL SURVEILLANCE;

EID: 85017663040     PISSN: 0899823X     EISSN: 15596834     Source Type: Journal    
DOI: 10.1017/ice.2017.42     Document Type: Review

References (160)

1. Surveillance atlas of infectious diseases. The European Centre for Disease Prevention and Control (ECDC) website. http://ecdc.europa.eu/en/healthtopics/antimicrobial-resistance/database/Pages/table-reports.aspx. Published 2015. Accessed October 9, 2016.
2. Munoz-Price LS, Quinn JP. Deconstructing the infection control bundles for the containment of carbapenem-resistant Enterobacteriaceae. Curr Opin Infect Dis 2013;26:378-387.
3. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008;52:1028-1033.
4. Ben-David D, Kordevani R, Keller N, Tal I, Marzel A, Gal-Mor O, Maor Y, Rahav G. Outcome of carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect 2012;18:54-60.
5. Borer A, Saidel-Odes L, Riesenberg K, et al. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol 2009;30:972-976.
6. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008;29:1099-1106.
7. Swaminathan M, Sharma S, Blash SP, et al. Prevalence and risk factors for acquisition of carbapenem-resistant Enterobacteriaceae in the setting of endemicity. Infect Control Hosp Epidemiol 2013;34:809-817.
8. Cornaglia G, Akova M, Amicosante G, et al. Metallo-betalactamases as emerging resistance determinants in Gram-negative pathogens: open issues. Int J Antimicrob Agents 2007;29: 380-388.
9. Chitnis AS, Caruthers PS, Rao AK, et al. Outbreak of carbapenem-resistant Enterobacteriaceae at a long-term acute care hospital: sustained reductions in transmission through active surveillance and targeted interventions. Infect Control Hosp Epidemiol 2012;33:984-992.
10. Grundmann H, Livermore DM, Giske CG, et al. Carbapenemnon- susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. Euro Surveill 2010;15:19711.
11. Glasner C, Albiger B, Buist G, et al. Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. Euro Surveill 2013;18:20525.
12. Prabaker K, Lin MY, McNally M, et al. Transfer from high-acuity long-term care facilities is associated with carriage of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae: A multihospital study. Infect Control 2012;33:1193-1199.
13. Bilavsky E, Schwaber MJ, Carmeli Y. How to stem the tide of carbapenemase-producing Enterobacteriaceae?: proactive versus reactive strategies. Curr Opin Infect Dis 2010;23:327-331.
14. Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013;13:785-796.
15. Cejas D, Fernández Canigia L, Rincón Cruz G, et al. First isolate of KPC-2-producing Klebsiella pneumoniae sequence Type 23 from the Americas. J Clin Microbiol 2014;52: 3483-5485.
16. Pitout JDD, Nordmann P, Poirel L. Carbapenemaseproducing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother 2015; 59:5873-5884.
17. Bonelli RR, Meurer Moreira B, Cristina Picão R. Antimicrobial resistance among Enterobacteriaceae in South America: History, current dissemination status and associated socioeconomic factors. Drug Resist Updates 2014;17:24-36.
18. Guh AY, Limbago BM, Kallen AJ. Epidemiology and prevention of carbapenem-resistant Enterobacteriaceae in the United States. Exp Rev Anti-infect Ther 2014;12:565-580.
19. Healthcare-associated infections. Tracking CRE. Centers for Disease Control and Prevention website. http://www.cdc.gov/hai/organisms/cre/TrackingCRE.html. Published 2015. Accessed October 15, 2016.
20. Hrabák J, Papagiannitsis CC, Študentová V, Jakubu V, Fridrichová M, Zemlickova H. Carbapenemase-producing Klebsiella pneumoniae in the Czech Republic in 2011. Euro Surveill 2013;18:20626.
21. Miró E, Agüero J, Larrosa MN, et al. Prevalence and molecular epidemiology of acquired AmpC β-lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain. Eur J Clin Microbiol Infect Dis 2013;32:253-259.
22. Jans B, Daniel Huang TD, Bauraing C, et al. Infection due to travel-related carbapenemase-producing Enterobacteriaceae, a largely underestimated phenomenon in Belgium. Acta Clinica Belgica 2015;70:181-187.
23. Denisuik AJ, Lagacé-Wiens PR, Pitout JD, et al. Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase-and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11. J Antimicrob Chemother 2013;68:i57-i65.
24. Kostyanev T, Tafaj S, Skenduli I, et al. First detection of KPC- 3-producing Klebsiella pneumoniae in Albania. New Microbes New Infect 2015;4:11.
25. Tängdén T, Giske CG. Global dissemination of extensively drugresistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control. J Int Med 2015;277:501-512.
26. Brink A, Coetzee J, Clay C, et al; L. The spread of carbapenemresistant Enterobacteriaceae in South Africa: Risk factors for acquisition and prevention. SAMJ: South African Med J 2012;102:599-601.
27. Saito R, Takahashi R, Sawabe E, et al. First Report of KPC-2 carbapenemase-producing Klebsiella pneumoniae in Japan. Antimicrob Agents Chemother 2014;58:2961-2963.
28. Markovska R, Stoeva T, Schneider I, et al. Clonal dissemination of multilocus sequence type ST15 KPC 2 producing Klebsiella pneumoniae in Bulgaria. APMIS 2015;23:887-894.
29. Rodríguez-Zulueta P, Silva-Sánchez J, Barrios H, et al. First outbreak of KPC-3-producing Klebsiella pneumoniae (ST258) clinical isolates in a Mexican Medical Center. Antimicrob Agents Chemother 2013;57:4086-4088.
30. Quiñones D, Hart M, Espinosa F, et al. Emergence of Klebsiella pneumoniae clinical isolates producing KPC-2-carbapenemase in Cuba. New Microbes New Infect 2014;2:123-126.
31. Pavelkovich A, Balode A, Edquist P, et al. Detection of carbapenemase-producing Enterobacteriaceae in the Baltic Countries and St. Petersburg Area. BioMed Res Int 2014; 7 pp. doi. org/10.1155/2014/548960.
32. Ageevets VA, Partina IV, Lisitsyna ES, et al. Emergence of carbapenemase-producing Gram-negative bacteria in Saint Petersburg, Russia. Int J Antimicrob Agents 2014;44:152-155.
33. Chua KYL, Grayson ML, Burgess AN, Lee JYH, Howden BP. The growing burden of multidrug-resistant infections among returned Australian travellers. Med J Aust 2014;200: 116-118.
34. Coatsworth NR, Huntington PG, Hardiman RP, Hudson BJ, Fernandes CJ. A case of carbapenemase-producing Klebsiella pneumoniae in Australia. Pathology 2012;44:42-44.
35. Chang LWK, Buising KL, Jeremiah CJ, et al. Managing a nosocomial outbreak of carbapenem-resistant Klebsiella pneumoniae: an early Australian hospital experience. Int Med J 2015;45:1037-1043.
36. Sheng WH, Badal RE, Hseuh P-R. Distribution of Extendedspectrum β-lactamases (ESBLs), AmpC β-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in Asia-Pacific: the Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 2013;57:2981-2988.
37. Lixandru BE, Cotar AI, Straut M, et al. Carbapenemaseproducing Klebsiella pneumoniae in Romania: a six-month survey. PloS One 2015;10(11). doi. 10.1371/journal.pone.0143214.
38. Zujić Atalić V, Bedenić B, Kocsis E, et al. Diversity of carbapenemases in clinical isolates of Enterobacteriaceae in Croatia-the results of a multicentre study. Clin Microbiol Infect 2014; 20:0894-0903.
39. Jones RN, Flonta M, Gurler N, Cepparulo M, Mendes RE, Castanheira M. Resistance surveillance program report for selected European nations2011Diagn Microbiol Infect Dis 2014;78:429-436.
40. Manenzhe RI, Zar HJ, Nicol MP, Kaba M. The spread of carbapenemase-producing bacteria in Africa: a systematic review. J Antimicrob Chemother 2015;70:23-40.
41. Ogbolu DO, Webber MA. High-level and novel mechanisms of carbapenem- resistance in Gram-negative bacteria from tertiary hospitals in Nigeria. Int J Antimicrob Agents 2014;43: 412-417.
42. Rimrang B, Chanawong A, Lulitanond A, et al. Emergence of NDM-1-and IMP-14a-producing Enterobacteriaceae in Thailand. J Antimicrob Chemother 2012;67:2626-2630.
43. Mushi MF, Mshana SE, Imirzalioglu C, Bwanga F. Carbapenemase genes among multidrug-resistant Gram-negative clinical isolates from a tertiary hospital in Mwanza, Tanzania. BioMed Res Int 2014. doi: 10.1155/2014/303104.
44. Peirano G, Lascols C, Hackel M, Hoban DJ, Pitout JDD. Molecular epidemiology of Enterobacteriaceae that produce VIMs and IMPs from the SMART surveillance program. Diagn Microbiol Infect Dis 2014;78:277-281.
45. Hawser SP, Bouchillon SK, Lascols C, et al. Susceptibility of Klebsiella pneumoniae isolates from intra-abdominal infections, and molecular characterization of ertapenem-resistant isolates. Antimicrob Agents Chemother 2011;55:3917-3922.
46. Huang XZ, Frye JG, Chahine MA, et al. Characteristics of plasmids in multi-drug-resistant Enterobacteriaceae isolated during prospective surveillance of a newly opened hospital in Iraq. PloS One 2012;7. doi: 10.1371/journal.pone.004036.
47. Jamal W, Rotimi VO, Albert MJ, Khodakhast F, Nordmann P, Poirel L. High prevalence of VIM-4 and NDM-1 metallo-β- lactamase among carbapenem-resistant Enterobacteriaceae. J Med Microbiol 2013;6:1239-1244.
48. Nastro M, Monge R, Zintgraff J, et al. First nosocomial outbreak of VIM 16 producing Serratia marcescens in Argentina. Clin Microbiol Infect 2013;19:617-619.
49. Lascols C, Hackel M, Marshall SH, et al. Increasing prevalence and dissemination of NDM-1 metallo-β-lactamase in India: data from the SMART study (2009). J Antimicrob Chemother 2011;66:1992-1997.
50. Nordmann P, Poirel L, Walsh TR, Livermore DM. The emerging NDM carbapenemases. Trends Microbiol 2011;19:588-595.
51. Barantsevich EP, Churkina IV, Barantsevich NE, Pelkonen J, Schlyakhto EV, Woodford N. Emergence of Klebsiella pneumoniae producing NDM-1 carbapenemase in Saint Petersburg, Russia. J Antimicrob Chemother 2013;68:1204-1206.
52. Brink AJ, Coetzee J, Clay CG, et al. Emergence of New Delhi metallo-beta-lactamase (NDM-1) and Klebsiella pneumoniae carbapenemase (KPC-2) in South Africa. J Clin Microbiol 2012;50:525-527.
53. Tran HH, Ehsani S, Shibayama K, et al. Common isolation of New Delhi metallo-beta-lactamase-1-producing Enterobacteriaceae in a large surgical hospital in Vietnam. Eur J Clin Microbiol Infect Dis 2015;34:1247-1254.
54. Berrazeg M, Diene SM, Medjahed L, et al. New Delhi metallobeta- lactamase around the world: an eReview using Google Maps. Eurosurveillance website. http://www.eurosurveillance. org/ViewArticle.aspx?ArticleId=20809. Published 2014. Accessed September 15, 2016.
55. Zowawi HM, Sartor AL, Balkhy HH, et al. Molecular characterization of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in the countries of the Gulf Cooperation Council: dominance of OXA-48 and NDM producers. Antimicrob Agents Chemother 2014;58:3085-3090.
56. Bastian S, Nordmann P, Creton E, et al. First case of NDM- 1-producing Klebsiella pneumoniae in Caribbean islands. Int J Infect Dis 2015;34:53-54.
57. Torres-González P, Bobadilla-del Valle M, Tovar-Calderón E, et al. Outbreak caused by Enterobacteriaceae harboring NDM-1 metallo-β-lactamase carried in an IncFII plasmid in a tertiary care hospital in Mexico City. Antimicrob Agents Chemother 2015;59:7080-7083.
58. Hrabák J, Študentová V, Adámková V, et al. Report on a transborder spread of carbapenemase-producing bacteria by a patient injured during Euromaidan, Ukraine. New Microbes New Infect 2015;8:28-30.
59. Poirel L, Héritier C, Tolün V, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004;48:15-22.
60. Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother 2012;67: 1597-1606.
61. Izdebski R, Bojarska K, Baraniak A, et al. NDM-1-or OXA-48- producing Enterobacteriaceae colonising Polish tourists following a terrorist attack in Tunis, March 2015. Euro Surveill2015; 20(23):21150.
62. Fursova NK, Astashkin EI, Knyazeva AI, et al. The spread of bla OXA-48 and bla OXA-244 carbapenemase genes among Klebsiella pneumoniae, Proteus mirabilis and Enterobacter spp. isolated in Moscow, Russia. Ann Clin Microbiol Antimicrob 2015;14:1.
63. Al-Agamy MH, Shibl AM, Elkhizzi NA, Meunier D, Turton JF, Livermore DM. Persistence of Klebsiella pneumoniae clones with OXA-48 or NDM carbapenemases causing bacteraemias in a Riyadh hospital. Diagn Microbiol Infect Dis 2013;76:214-216.
64. Matar GM, Cuzon G, Araj F, et al. Oxacillinase-mediated resistance to carbapenems in Klebsiella pneumoniae from Lebanon. Clin Microbiol Infect 2008;14:887-888.
65. Cuzon G, Naas T, Lesenne A, Benhamou M, Nordmann P. Plasmid-mediated carbapenem-hydrolysing OXA-48 β-lactamase in Klebsiella pneumoniae from Tunisia. Int J Antimicrob Agents 2010;36:91-93.
66. Lafeuille E, Decré D, Mahjoub-Messai F, Bidet P, Arlet G, Bingen E. OXA-48 carbapenemase-producing Klebsiella pneumoniae isolated from Libyan patients. Microbial Drug Resist 2013;19:491-497.
67. Brink AJ, Coetzee J, Corcoran C, et al. Emergence of OXA-48 and OXA-181 carbapenemases among Enterobacteriaceae in South Africa and evidence of in vivo selection of colistin resistance as a consequence of selective decontamination of the gastrointestinal tract. J Clin Microbiol 2013;51:369-372.
68. Lascols C, Peirano G, Hackel M, Laupland KB, Pitout JD. Surveillance and molecular epidemiology of Klebsiella pneumoniae that produce carbapenemases; the first report of OXA-48-like enzymes in North America. Antimicrob Agents Chemother 2013;57:130-136.
69. Williamson DA, Heffernan H, Sidjabat H, et al. Intercontinental transfer of OXA-181-producing Klebsiella pneumoniae into New Zealand. J Antimicrob Chemother 2011;66:2888-2890.
70. Biedenbach D, Bouchillon S, Hackel M, et al. Dissemination of NDM metallo-β-lactamase genes among clinical isolates of Enterobacteriaceae collected during the SMART global surveillance study from 2008 to 2012. Antimicrob Agents Chemother 2015;59:826-830.
71. Teo JW, Kurup A, Lin RT, Hsien KT. Emergence of clinical Klebsiella pneumoniae producing OXA-232 carbapenemase in Singapore. New Microbes New Infect 2013;1:13-15.
72. Jao Y, Lee PS, Hung CT, et al. First report of OXA-48 carbapenemase-producing Escherichia coli in Taiwan. Antimicrob Resist Infect Control 2015;4(Suppl 1):126.
73. Djahmi N, Dunyach-Remy C, Pantel A, Dekhil M, Sotto A, Lavigne JP. Epidemiology of carbapenemase-producing Enterobacteriaceae and Acinetobacter baumannii in Mediterranean countries. BioMed Res Int 2014;2014:305784.
74. Samuelsen Ø, Naseer U, Karah N, et al. Identification of Enterobacteriaceae isolates with OXA-48 and coproduction of OXA-181 and NDM-1 in Norway. J Antimicrob Chemother 2013;68:1682-1685.
75. Walkty A, Gilmour M, Simner P, et al. Isolation of multiple carbapenemase-producing Gram-negative bacilli from a patient recently hospitalized in Nigeria. Diagn Microbiol Infect Dis 2015;81:296-298.
76. Carbapenem-resistant Enterobacteriaceae. California Department of Public Health website. http://www.cdph.ca.gov/programs/hai/Pages/Carbapenem-ResistantEnterobacteriaceae.aspx. Accessed September 25, 2016.
77. Centers for Disease Control and Prevention. Guidance for control of infections with carbapenem-resistant or carbapenemaseproducing Enterobacteriaceae in acute care facilities. Morb Mortal Wkly Rep 2009;58:256-260.
78. Carmeli Y, Akova M, Cornaglia G, et al. Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control. Clin Microbiol Infect 2010;16:102-111.
79. Samra Z, Bahar J, Madar-Shapiro L, Aziz N, Israel S, Bishara J. Evaluation of CHROMagar KPC for rapid detection of carbapenem-resistant Enterobacteriaceae. J Clin Microbiol 2008;46:3110-3111.
80. Carrer A, Fortineau N, Nordmann P. Use of ChromID extended-spectrum beta-lactamase medium for detecting carbapenemase-producing Enterobacteriaceae. J Clin Microbiol 2010;48:1913-1914.
81. Adler A, Navon-Venezia S, Moran-Gilad J, Marcos E, Schwartz D, Carmeli Y. Laboratory and clinical evaluation of screening agar plates for detection of carbapenem-resistant Enterobacteriaceae from surveillance rectal swabs. J Clin Microbiol 2011;49:2239-2242.
82. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009;9:228-236.
83. Wertheim HF, Vos MC, Boelens HA, et al. Low prevalence of methicillin-resistant Staphylococcus aureus (MRSA) at hospital admission in the Netherlands: the value of search and destroy and restrictive antibiotic use. J Hosp Infect 2004;56:321-325.
84. Kluytmans-VandenBergh MFQ, Kluytmans JAJW, Voss A. Dutch guideline for preventing nosocomial transmission of highly resistant microorganisms (HRMO). Infection 2005; 33:309-313.
85. Akova M, Daikos GL, Tzouvelekis L, Carmeli Y. Interventional strategies and current clinical experience with carbapenemaseproducing Gram-negative bacteria. Clin Micro Infect 2012;18: 439-448.
86. McGrath EJ, Chopra T, Abdel-Haq N, et al. An outbreak of carbapenem-resistant Acinetobacter baumannii infection in a neonatal intensive care unit: investigation and control. Infect Control Hosp Epidemiol 2011;32:34-41.
87. Schwaber MJ, Carmeli Y. An ongoing national intervention to contain the spread of carbapenem-resistant Enterobacteriaceae. Clin Infect Dis 2014;58:697-703.
88. Kotsanas D, Wijesooriya WR, Korman TM, et al. "Down the drain": carbapenem-resistant bacteria in intensive care unit patients and handwashing sinks. Med J Aust 2013;198: 267-269.
89. Needleman J, Buerhaus P, Mattke S, Stewart M, Zelevinsky K. Nurse-staffing levels and the quality of care in hospitals. N Engl J Med 2002;346:1715-1722.
90. Fedorowsky R, Peles-Bortz A, Masarwa S, Liberman D, Rubinovitch B, Lipkin V. Carbapenem-resistant Enterobacteriaceae carriers in acute care hospitals and postacute-care facilities: The effect of organizational culture on staff attitudes, knowledge, practices, and infection acquisition rates. Am J Infect Control 2015;43:935-939.
91. Siegel JD, Rhinehart E, Jackson M, Chiarello L. 2007 guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control. 2007(35): S65-S164.
92. Wiener-Well Y, Rudensky B, Yinnon AM, et al. Carriage rate of carbapenem-resistant Klebsiella pneumoniae in hospitalised patients during a national outbreak. J Hosp Infect 2010; 74:344-349.
93. Löfmark S, Sjöström K, Mäkitalo B, Edquist P, Tegmark Wisell K, Giske CG. Carbapenemase-producing Enterobacteriaceae in Sweden 2007-2013: Experiences from seven years of systematic surveillance and mandatory reporting. Drug Resist Updates (2015).
94. Matthaiou DK, Michalopoulos A, Rafailidis PI, et al. Risk factors associated with the isolation of colistin-resistant Gram-negative bacteria: a matched case-control study. Crit Care Med 2008;36:807-811.
95. Lerner A, Romano J, Chmelnitsky I, Navon-Venezia S, Edgar R, Carmeli Y. Rectal swabs are suitable for quantifying the carriage load of KPC-producing carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother 2013;57:1474-1479.
96. Thurlow CJ, Prabaker K, Lin MY, Lolans K, Weinstein RA, Hayden MK. Anatomic sites of patient colonization and environmental contamination with Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae at long-term acute care hospitals. Infect Control Hosp Epidemiol 2013;34:56-61.
97. Schwaber MJ, Lev B, Israeli A, et al. Containment of a countrywide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli Hospitals via a nationally implemented intervention. Clin Infect Dis 2011;52:848-855.
98. WHO guidelines on hand hygiene in health care. World Health Organization website. http://apps.who.int/iris/bitstream/10665/44102/1/9789241597906-eng.pdf. Accessed January 21, 2017.
99. Sax H, Allegranzi B, Uckay I, Larson E, Boyce J, Pittet D. 'My five moments for hand hygiene': a user-centred design approach to understand, train, monitor and report hand hygiene. J Hosp Infect 2007;67:9-21.
100. Lledo W, Hernandez M, Lopez E, et al. Guidance for control of infections with carbapenem-resistant or carbapenemaseproducing Enterobacteriaceae in acute care facilities. Morbid Mortal Wkly Rep 2009;58:256-260.
101. Schechner V, Kotlovsky T, Tarabeia J, et al. Predictors of rectal carriage of carbapenem-resistant Enterobacteriaceae (CRE) among patients with known CRE carriage at their next hospital encounter. Infect Control Hosp Epidemiol 2011;32:497-503.
102. Ben-David D, Masarwa S, Navon-Venezia S, et al. Carbapenemresistant Klebsiella pneumoniae in post-acute-care facilities in Israel. Infect Control Hosp Epidemiol 2011;32:845-853.
103. Lewis JD, Enfield KB, Mathers AJ, Giannetta ET, Sifri CD. The limits of serial surveillance cultures in predicting clearance of colonization with carbapenemase-producing Enterobacteriaceae. Infect Control Hosp Epidemiol 2015;36:1-3.
104. Feldman N, Adler A, Molshatzki N, et al. Gastrointestinal colonization by KPC-producing Klebsiella pneumoniae following hospital discharge: duration of carriage and risk factors for persistent carriage. Clin Microbiol Infect 2013;19:E190-E196.
105. Oren I, Sprecher H, Finkelstein R, et al. Eradication of carbapenem-resistant Enterobacteriaceae gastrointestinal colonization with nonabsorbable oral antibiotic treatment: a prospective controlled trial. Am J Infect Control 2013;41:1167-1172.
106. Facility guidance for control of carbapenem-resistant Enterobacteriaceae (CRE)-November 2015 update CRE toolkit. Centers for Disease Control and Prevention website. https://www.cdc.gov/hai/organisms/cre/cre-toolkit/. Published 2015. Accessed October 2, 2016.
107. Carbapenemase-producing Enterobacteriaceae: early detection, management and control toolkit for acute trusts. Public Health England website. https://www.gov.uk/government/publications/carbapenemase-producing-enterobacteriaceae-early-detectionmanagement- and-control-toolkit-for-acute-trusts. Published 2014. Accessed October 2, 2016.
108. Ben-David D, Masarwa S, Adler A, Mishali H, Carmeli Y, Schwaber MJ. A national intervention to prevent the spread of carbapenem-resistant Enterobacteriaceae in Israeli post-acute care hospitals. Infect Control Hosp Epidemiol 2014;35:802-809.
109. Hand hygiene in outpatient and home-based care and long-term care facilities. World Health Organization website. http://www.who.int/gpsc/en/. Published 2016. Accessed October 2, 2016.
110. Rogers BA, Aminzadeh Z, Hayashi Y, Paterson DL. Countryto- country transfer of patients and the risk of multi-resistant bacterial infection. Clin Infect Dis 2011;53:49-56.
111. Lerner A, Solter E, Rachi E, et al. Detection and characterization of carbapenemase-producing Enterobacteriaceae in wounded Syrian patients admitted to hospitals in northern Israel. Eur J Clin Microbiol Infect Dis 2015:1-6.
112. Reichel M, Schlicht A, Ostermeyer C, Kampf G. Efficacy of surface disinfectant cleaners against emerging highly resistant Gram-negative bacteria. BMC Infect Dis 2014;14:292.
113. Jawad A, Seifert H, Snelling AM, et al. Survival of Acinetobacter baumannii on dry surfaces: comparison of outbreak and sporadic isolates. J Clin Microbiol 1998;36:1938-1941.
114. Olson B, Weinstein RA, Nathan C. Epidemiology of endemic Pseudomonas aeruginosa: why infection control efforts have failed. J Infect Dis 1984;150:808-816.
115. Simor AE, Lee M, Vearncombe M. An outbreak due to multiresistant Acinetobacter baumannii in a burn unit: risk factors for acquisition and management. Infect Control Hosp Epidemiol 2002;23:261-267.
116. Nseir S, Blazejewski C, Lubret R, Wallet F, Courcol R, Durocher A. Risk of acquiring multidrug-resistant Gramnegative bacilli from prior room occupants in the intensive care unit. Clin Micro Infect 2011;17:1201-1208.
117. Weber DJ, Rutala WA, Kanamori H, Gergen MF, Sickbert-Bennett EE. Carbapenem-Resistant Enterobacteriaceae: frequency of hospital room contamination and survival on various inoculated surfaces. Infect Control Hosp Epidemiol 2015;36: 590-593.
118. Cochard H, Aubier B, Quentin R, van der Mee-Marquet N. Extended-spectrum β-lactamase-producing Enterobacteriaceae in French nursing homes: an association between high carriage rate among residents, environmental contamination, poor conformity with good hygiene practice, and putative residentto- resident transmission. Infect Control Hosp Epidemiol 2014;35:384-389.
119. Public Health Agency of Canada. Guidance: Infection prevention and control measures for health workers in all health settings. Carbapenem-resistant Gram-negative bacilli. http://www.phac-aspc.gc.ca/nois-sinp/guide/ipcm-mpci/ipcm-mpci-eng. php. Published 2010. Accessed October 15, 2016.
120. Harris AD, Perencevich EN, Johnson JK, et al. Patient-to-patient transmission is important in extended-spectrum β-lactamase- producing Klebsiella pneumoniae acquisition. Clin Infect Dis 2007;45:1347-1350.
121. Hilty M, Betsch BY, Bögli-Stuber K, et al. Transmission dynamics of extended-spectrum β-lactamase-producing Enterobacteriaceae in the tertiary care hospital and the household setting. Clin Infect Dis 2012;55:967-975.
122. Rodríguez-Baño J, Navarro MD, Romero L, et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004;42:1089-1094.
123. Tschudin-Sutter S, Frei R, Dangel M, Stranden A, Widmer AF. Rate of transmission of extended-spectrum beta-lactamase- producing Enterobacteriaceae without contact isolation. Clin Infect Dis 2012:cis770.
124. Weinstein RA. Insights into the epidemiology and control of infection with vancomycin-resistant enterococci. Clin Infect Dis 2000;31:1058-1065.
125. Donlan RM. Biofilms: microbial life on surfaces. Emerg Infect Dis 2002;8:881-890.
126. de Jager P, Chirwa T, Naidoo S, Perovic O, Thomas J. Nosocomial outbreak of New Delhi metallo-β-lactamase- 1-producing Gram-negative bacteria in South Africa: a casecontrol study. PloS One 2015;10:e0123337.
127. Gould CV, Umscheid CA, Agarwal RK, Kuntz G, Pegues DA. and Healthcare Infection Control Practices Advisory Committee Guideline for prevention of catheter-associated urinary tract infections 2009. Infect Control Hosp Epidemiol 2010;31: 319-326.
128. Vernon MO, Hayden MK, Trick WE, Hayes RA, Blom DW, Weinstein RA. Chlorhexidine gluconate to cleanse patients in a medical intensive care unit: the effectiveness of source control to reduce the bioburden of vancomycin-resistant enterococci. Arch Intern Med 2006;166:306-312.
129. Climo MW, Yokoe DS, Warren DK, et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. N Engl J Med 2013;368:533-542.
130. Munoz-Price LS, Hota B, Stemer A, Weinstein RA. Prevention of bloodstream infections by use of daily chlorhexidine baths for patients at a long-term acute care hospital. Infect Control Hosp Epidemiol 2009;30:1031-1035.
131. Derde LPG, Cooper BS, Goossens H, et al. Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial. Lancet Infect Dis 2014; 14:31-39.
132. Hayden MK, Lin MY, Lolans K, et al. Prevention of colonization and infection by Klebsiella pneumoniae carbapenemase- producing Enterobacteriaceae in long-term acute-care hospitals. Clin Infect Dis 2015;60:1153-1161.
133. de Smet AMGA, Kluytmans JAJW, Cooper BS, et al. Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med 2009;360:20-31.
134. Shibli AB, Milbrandt EB, Baldisseri M. Dirty mouth? Should you clean it out? Decontamination for the prevention of pneumonia and mortality in the ICU. Crit Care 2010;14:314.
135. Zuckerman T, Benyamini N, Sprecher H, et al. SCT in patients with carbapenem- resistant Klebsiella pneumoniae: A single center experience with oral gentamicin for the eradication of carrier state. Bone Marrow Transplant 2010. doi: 10.1038/bmt.2010.279.
136. Manges AR, Steiner TS, Wright AJ. Fecal microbiota transplantation for the intestinal decolonization of extensively antimicrobial-resistant opportunistic pathogens: a review. Infect Dis 2016;10:1-6.
137. Fournier S, Monteil C, Lepainteur M, et al. Long-term control of carbapenemase-producing Enterobacteriaceae at the scale of a large French multihospital institution: a nine-year experience, France, 2004 to 2012. Euro Surveill 2014;19.
138. Österblad M, Kirveskari J, Hakanen AJ, Tissari P, Vaara M, Jalava J. Carbapenemase-producing Enterobacteriaceae in Finland: the first years (2008-11). J Antimicrob Chemother 2012;67:2860-2864.
139. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenemresistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011;53:60-67.
140. Canadian Integrated Program for Antimicrobial Resistance (CIPARS). Public Health Agency of Canada website. http://www.phac-aspc.gc.ca/cipars-picra/index-eng.php. Published 2007. Accessed October 19, 2016.
141. What is AGAR? Australasian Group on Antimicrobial Resistance (AGAR) website. http://www.agargroup.org/whatis. Published 2004. Accessed October 19, 2016.
142. WHO. WHO global strategy for containment of antimicrobial resistance. Geneva: WHO; 2001.
143. WHO. The evolving threat of antimicrobial resistance: options for action. Geneva: WHO; 2012.
144. Dumartin C, Rogues AM, Amadeo B, et al. Antibiotic usage in southwestern French hospitals: trends and association with antibiotic stewardship measures. J Antimicrob Chemother 2011;66:1631-1637.
145. Colligan C, Sneddon J, Bayne G, Malcolm W, Walker G, Nathwani D. Six years of a national antimicrobial stewardship programme in Scotland: where are we now? Antimicrob Resist Infect Control 2015;4:1-5.
146. Howard P, Pulcini C, Levy Hara G, et al. An international crosssectional survey of antimicrobial stewardship programmes in hospitals. J Antimicrob Chemother 2015;70:1245-1255.
147. Jamtvedt G, Young JM, Kristoffersen DT, O'Brien MA, Oxman AD. Audit and feedback: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2006;2(2).
148. Chen JH, Siu LK, Fung CP, et al. Contribution of outer membrane protein K36 to antimicrobial resistance and virulence in Klebsiella pneumoniae. J Antimicrob Chemother 2010;65:986-990.
149. Giske CG, Fröding I, Hasan CM, et al. Diverse sequence types of Klebsiella pneumoniae contribute to the dissemination of blaNDM-1 in India, Sweden, and the United Kingdom. Antimicrob Agents Chemother 2012;56:2735-2738.
150. Deshpande LM, Jones RN, Fritsche TR, Sader HS. Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004). Microbiol Drug Resist 2006;12: 223-230.
151. Sievert DM, Ricks P, Edwards JR, et al, and for the National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013;34:1-14.
152. Central Asian and Eastern European surveillance of antimicrobial resistance. World Health Organization Europe website. http://www.euro.who.int/-data/assets/pdf-file/0006/285405/CAESARSurveillance- Antimicrobial-Resistance2014.pdf?ua=1. Published 2014. Accessed October 2, 2016.
153. Study for monitoring antimicrobial resistant trends (SMART)- IFPM. International Federation of Pharmaceutical Manufacturers website. http://partnerships.ifpma.org/partnership/study-formonitoring-antimicrobial-resistance-trends-smart. Published 2016. Accessed January 23, 2017.
154. Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis 2011; 11:355-362.
155. Scotta C, Juan C, Cabot G, et al. Environmental microbiota represents a natural reservoir for dissemination of clinically relevant metallo-β-lactamases. Antimicrob Agents Chemother 2011;55:5376-5379.
156. Chagas TP, Seki LM, da Silva DM, Asensi MD. Occurrence of KPC-2-producing Klebsiella pneumoniae strains in hospital wastewater. J Hosp Infect 2011;77:281.
157. Knaizeh EG, Workman SN. Carbapenemase-producing Enterobacteriaceae detected in sewage on the island of Barbados. Presented at Caribbean Public Health Agency 59th Annual Scientific Meeting, May 2014. Caribbean Public Health Agency website. http://conference.carpha.org/Portals/0/docs/CARPHA-CHRC-Programme.pdf. Published 2014. Accessed October 10, 2016.
158. Abdallah HM, Reuland EA, Wintermans BB, et al. Extendedspectrum β-lactamases and/or carbapenemases-producing Enterobacteriaceae isolated from retail chicken meat in Zagazig, Egypt. PloS One 2015;10:e0136052.
159. Zurfluh K, Poirel L, Nordmann P, Klumpp J, Stephan R. First detection of Klebsiella variicola producing OXA-181 carbapenemase in fresh vegetable imported from Asia to Switzerland. Antimicrob Resist Infect Control 2015;4:1-3.
160. SchwaberMJ, Carmeli Y. Carbapenem-resistant Enterobacteriaceae: a potential threat. JAMA 2008;300:2911-2913.